MPL and congenital secretory chloride diarrhea 1: Based on the outcomes of the ADAPT-1 and ADAPT-2 trials, avatrombopag, a second-generation thrombopoietin receptor agonist (TPO-RAs), which activates the c-Mpl TPO receptor and stimulates proliferation and differentiation of megakaryocytes [9], has been approved by the US FDA for treatment of patients with thrombocytopenia and CLD who need to undergo an invasive procedure [10, 11].